290 related articles for article (PubMed ID: 25499347)
1. Sitagliptin and the risk of hospitalization for heart failure: a population-based study.
Wang KL; Liu CJ; Chao TF; Huang CM; Wu CH; Chen SJ; Yeh CM; Chen TJ; Lin SJ; Chiang CE
Int J Cardiol; 2014 Nov; 177(1):86-90. PubMed ID: 25499347
[TBL] [Abstract][Full Text] [Related]
2. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
McGuire DK; Van de Werf F; Armstrong PW; Standl E; Koglin J; Green JB; Bethel MA; Cornel JH; Lopes RD; Halvorsen S; Ambrosio G; Buse JB; Josse RG; Lachin JM; Pencina MJ; Garg J; Lokhnygina Y; Holman RR; Peterson ED;
JAMA Cardiol; 2016 May; 1(2):126-35. PubMed ID: 27437883
[TBL] [Abstract][Full Text] [Related]
3. No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.
Chang CH; Chang YC; Lin JW; Caffrey JL; Wu LC; Lai MS; Chuang LM
Int J Cardiol; 2016 Oct; 220():14-20. PubMed ID: 27389437
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
[TBL] [Abstract][Full Text] [Related]
5. Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study.
Fu AZ; Johnston SS; Ghannam A; Tsai K; Cappell K; Fowler R; Riehle E; Cole AL; Kalsekar I; Sheehan J
Diabetes Care; 2016 May; 39(5):726-34. PubMed ID: 26740636
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
7. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study.
Weir DL; McAlister FA; Senthilselvan A; Minhas-Sandhu JK; Eurich DT
JACC Heart Fail; 2014 Dec; 2(6):573-82. PubMed ID: 24998080
[TBL] [Abstract][Full Text] [Related]
8. Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.
Toh S; Hampp C; Reichman ME; Graham DJ; Balakrishnan S; Pucino F; Hamilton J; Lendle S; Iyer A; Rucker M; Pimentel M; Nathwani N; Griffin MR; Brown NJ; Fireman BH
Ann Intern Med; 2016 Jun; 164(11):705-14. PubMed ID: 27110660
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Najafzadeh M; Koeneman L; Farsani SF; Déruaz-Luyet A; Paik JM; Patorno E
JAMA Netw Open; 2022 Oct; 5(10):e2237606. PubMed ID: 36264574
[TBL] [Abstract][Full Text] [Related]
10. All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
Scheller NM; Mogensen UM; Andersson C; Vaag A; Torp-Pedersen C
Diabetes Obes Metab; 2014 Mar; 16(3):231-6. PubMed ID: 24020750
[TBL] [Abstract][Full Text] [Related]
11. Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry.
Fadini GP; Saragoni S; Russo P; Degli Esposti L; Vigili de Kreutzenberg S; Melazzini M; Avogaro A;
Diabetes Obes Metab; 2017 Oct; 19(10):1416-1424. PubMed ID: 28432754
[TBL] [Abstract][Full Text] [Related]
12. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
[TBL] [Abstract][Full Text] [Related]
13. Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: A population-based cohort study.
Hung YC; Lin CC; Huang WL; Chang MP; Chen CC
Sci Rep; 2016 Jul; 6():30499. PubMed ID: 27460913
[TBL] [Abstract][Full Text] [Related]
14. Sitagliptin and heart failure hospitalization in patients with type 2 diabetes.
Tseng CH
Oncotarget; 2016 Sep; 7(38):62687-62696. PubMed ID: 27409676
[TBL] [Abstract][Full Text] [Related]
15. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.
Fadini GP; Avogaro A; Degli Esposti L; Russo P; Saragoni S; Buda S; Rosano G; Pecorelli S; Pani L;
Eur Heart J; 2015 Sep; 36(36):2454-62. PubMed ID: 26112890
[TBL] [Abstract][Full Text] [Related]
16. Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors.
Scirica BM; Im K; Murphy SA; Kuder JF; Rodriguez DA; Lopes RD; Green JB; Ruff CT; Sabatine MS
Clin Cardiol; 2022 Jul; 45(7):794-801. PubMed ID: 35715946
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
[TBL] [Abstract][Full Text] [Related]
18. Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study.
Lee YC; Chang CH; Dong YH; Lin JW; Wu LC; Hwang JS; Chuang LM
Int J Cardiol; 2017 Feb; 228():1007-1014. PubMed ID: 27923207
[TBL] [Abstract][Full Text] [Related]
19. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study.
Chen DY; Wang SH; Mao CT; Tsai ML; Lin YS; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Chen TH
Int J Cardiol; 2015 Feb; 181():200-6. PubMed ID: 25528312
[TBL] [Abstract][Full Text] [Related]
20. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
